Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged  ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023

Euro Surveill. 2024 Jan;29(1). doi: 10.2807/1560-7917.ES.2024.29.1.2300670.ABSTRACTTo monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-olds.PMID:38179626 | DOI:10.2807/1560-7917.ES.2024.29.1.2300670

Source: Euro Surveill - January 5, 2024 Category: Infectious Diseases Authors: Mario Font án-Vela Esther Kissling Nathalie Nicolay Toon Braeye Izaak Van Evercooren Christian Holm Hansen Hanne-Dorthe Emborg Massimo Fabiani Alberto Mateo-Urdiales Ala'a AlKerwi Susanne Schmitz Jes ús Castilla Iv án Martínez-Baz Brechje de Gier Susa Source Type: research